#None #Stockholm #Hematology #Eli Lilly #EHA Meeting

Eli Lilly to Highlight New Developments in Hematology

At the upcoming 2026 European Hematology Association (EHA) Annual Meeting in Stockholm, Eli Lilly and Company (NYSE: LLY) will present significant advancements in its hematology portfolio. The meeting, scheduled for June 11-14, will underscore results from several landmark clinical studies, showcasing Lilly's commitment to innovation in blood disorder therapies.

Key Presentation: Phase 3 BRUIN CLL-322 Study

One of the standout presentations will cover the Phase 3 BRUIN CLL-322 study, which examines the efficacy of Jaypirca (pirtobrutinib) in combination with venetoclax and rituximab versus venetoclax and rituximab alone for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). This late-breaking oral presentation is particularly noteworthy as it represents the first Phase 3 trial in CLL that demonstrates superior outcomes compared to a venetoclax-based control group.

Jacob Van Naarden, executive vice president and president of Lilly Oncology, praised the significance of this data, stating, "This represents a crucial advancement for patients struggling with CLL. The results show that the addition of Jaypirca not only improves outcomes but elevates the standard of care for this challenging disease."

Ajax and Kelonia Therapeutics' Contributions

Complementing Lilly's own discoveries, presentations from Ajax Therapeutics and Kelonia Therapeutics will also be crucial as both companies are set to be acquired by Lilly, pending regulatory approvals. Ajax will share results from its Phase 1 AJX-101 trial focusing on AJ1-11095, an innovative type II JAK2 inhibitor aimed at patients with myelofibrosis who have not responded to type I JAK2 inhibitors. This will be their first public disclosure of clinical data.

Kelonia will enhance the dialogue surrounding CAR-T therapies by presenting new findings from their inMMyCAR study, which targets BCMA in patients with multiple myeloma. As these therapies show promise, they signify Lilly's growing footprint in the treatment of hematological malignancies.

Presentation Details

Among the highlights:

• - Jaypirca (pirtobrutinib): Results showcasing the success of combined therapies in improving progression-free survival in patients with previously treated CLL.
• - AJX-101: The first clinical results demonstrating the efficacy of a new class of JAK2 inhibitors for myelofibrosis patients.
• - KLN-1010: Additional insights from the Phase 1 trial on CAR-T strategies for multiple myeloma, contributing to improving treatment regimens for this challenging condition.

The EHA Annual Meeting is poised to be a pivotal point in bringing together researchers, healthcare professionals, and industry experts to discuss these significant advancements. It emphasizes Lilly's ongoing mission to provide life-changing treatments and improve the quality of life for patients battling blood diseases.

Commitment to Innovation

Eli Lilly's dedication to advancing hematology solutions illustrates its overall strategy of leveraging innovative science and clinical research. The data presented at EHA not only reinforces their existing treatment options but also sets the stage for future advancements and potential new therapies that could reshape the landscape of hematological care.

For more information about Lilly's hematology initiatives, interested parties can visit Lilly.com for the latest updates and research contributions leading to breakthroughs in patient care.